Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2011

View Archived Issues

Kowa gains rights to anagliptin in two Asian countries

Study suggests serotonin reuptake inhibitors reduce brain amyloid plaques

New biomarker stratifies subjects with low LDL-C and high hsCRP for risk of cardiovascular disease

Researchers identify new ALS-linked gene and find common cause for all forms of the disease

Merck KGaA divulges novel TbetaR-I inhibitors

New DNA replication and repair protein inhibitors presented by STC.UNM

CSIR claims novel anticancer artemisinin derivatives

Korean company prepares novel inducers of apoptosis

First BBB-penetrating biologic TNF inhibitors developed

New H-PGDS inhibitors patented by Taiho

BioTime subsidiary receives funding to expand development of cancer diagnostics and therapeutics

Apceth somatic cell therapy enters phase I/II trial

FDA grants orphan drug status to Pluristem's PLX cells

Tekmira obtains license to Halo-Bio RNAi technology

RxGen and miRagen receive NIH grant for microRNA collaboration

Boehringer Ingelheim and Lilly obtain European approval for linagliptin

Monoglyceride lipase inhibitor prevents gastric hemorrhage and reduces symptoms of colitis in vivo

QRxPharma completes NDA submission for IR dual opioid pain therapy

First iguratimod product approved in China

FDA approves Shire's Firazyr

Quadrivalent HPV vaccine Gardasil launched in Japan

Alimentary Health and Norgine enter partnership

Bionor Pharma to conduct exploratory study of HIV vaccine candidate with lenalidomide

Medistem files response to FDA's clinical hold on its IND for endometrial regenerative cells

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...